Pfizer/BioNTech bid for booster doses premature, more data needed - experts
Pfizer Inc's push for health regulators to authorise a third dose of its Covid-19 shot is not yet backed by evidence, despite the fast-spreading Delta variant, vaccine experts said.
Pfizer and German partner BioNTech SE said last week that they will ask US and European regulators within weeks to authorise a booster dose due to an increased risk of infection after six months.
The companies did not share the data showing...
Verifying user
RM12.50 / month
- Unlimited access to award-winning journalism
- Comment and share your opinions on all our articles
- Gift interesting stories to your friends
- Tax deductable